Paoletti Pierre, Neyton Jacques
Laboratoire de Neurobiologie, CNRS UMR 8544 Ecole Normale Supérieure 46 rue d'Ulm, 75005 Paris, France.
Curr Opin Pharmacol. 2007 Feb;7(1):39-47. doi: 10.1016/j.coph.2006.08.011. Epub 2006 Nov 7.
N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels widely expressed in the central nervous system that play key roles in excitatory synaptic transmission. Because of their involvement in numerous neurological disorders, NMDARs are also targets of therapeutic interest. NMDARs occur as multiple subtypes which differ in their subunit composition and in their biophysical and pharmacological properties. In particular, NMDARs contain a diversity of sites at which endogenous ligands or pharmacological agents can act to modulate receptor activity in a subunit-selective manner, and recent structural and functional data have started to reveal the molecular determinants for this subunit selectivity. These include the binding sites for glutamate, the ion-channel pore and the recently identified allosteric sites on the N-terminal domain. Other potential sites yet unexplored by medicinal chemistry programs are also considered, in particular at the interface between subunits. Given the growing body of evidence that diverse brain disorders implicate different NMDAR subtypes, such as NR2B in pain or NR3A in white matter injury, there is a growing interest in exploiting the pharmacological heterogeneity of NMDARs for the development of novel NMDAR subtype-selective compounds.
N-甲基-D-天冬氨酸受体(NMDARs)是谷氨酸门控离子通道,在中枢神经系统中广泛表达,在兴奋性突触传递中起关键作用。由于它们与多种神经系统疾病有关,NMDARs也是具有治疗意义的靶点。NMDARs以多种亚型形式存在,其亚基组成以及生物物理和药理特性各不相同。特别是,NMDARs含有多种位点,内源性配体或药理剂可作用于这些位点,以亚基选择性方式调节受体活性,最近的结构和功能数据已开始揭示这种亚基选择性的分子决定因素。这些包括谷氨酸结合位点、离子通道孔以及N端结构域上最近确定的变构位点。药物化学项目尚未探索的其他潜在位点也被考虑在内,特别是在亚基之间的界面处。鉴于越来越多的证据表明,多种脑部疾病涉及不同的NMDAR亚型,如疼痛中的NR2B或白质损伤中的NR3A,人们越来越有兴趣利用NMDARs的药理异质性来开发新型NMDAR亚型选择性化合物。